phase 2 trial of panitumumab and irinotecan in previously oxaliplatin and irinotecan refractory patients with colorectal cancer

Phase 2

• Conditions: Colorectal Cancer

• Registration Number: JPRN-UMIN000004500
• Lead Sponsor: Jichi medical university

Brief Summary

https://www.spandidos-publications.com/ol/11/6/4049/abstract

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-11-02
• Study Completion: 2012-09-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Exclusion Criteria

1) symptomatic brain metastasis 2) waterly diarrhea 3) Paralytic or mechanical bowel obstruction 4) severe infectious disease 5) severe plumonary disease (interstitial lung disease or plumonary fibrosis) 6) severe complications (uncontrolable diabetes, heart failure NYHA>=III, renal failure, liver failure) 7) Pregnant or lactating women or women of childbearing potential 8) carcinomatosis meningitis 9) peripheral neuropathy Grade>=3 10)Need to treatment with flucytosine, atazanavir sulfate 11) history of Grade>=3 hypersensitivity due to monoclonal antibody therapy 12) history of Grade>=3 hypersensitivity due to irinotecan 13) history of treatment of anti EGFR pathway 14) patients judged inappropriate for this study by physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
response rate

Secondary Outcome Measures

Name	Time	Method
disease control rate, duration of response, progression free survival, overall survival, incidence of adverse events.